Most drugs are metabolized by CYP3A enzymes, and variations in expression levels of these enzymes are believed to determine whether patients will have a positive or adverse drug response.

Pregnancy. Nursing mothers. See Contraindications. Concomitant moderate CYP3A inducers: not recommended. May be potentiated by combined P-gp, UGT1A1, and strong CYP3A inhibitors: concomitant use ...

Potentiated by moderate or weak CYP3A inhibitors (eg, nefazodone, fluvoxamine, cimetidine, erythromycin); avoid or reduce alprazolam dose. Antagonized by CYP3A inducers (eg, carbamazepine ...

Because CYP isoenzymes metabolize a large number of structurally diverse drugs and chemicals, most of the variant genotypes of the CYP2D6, CYP2C9, CYP2C19, and CYP3A families have been identified ...

Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers. Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates prescribing ...